title: MYC/BCL2 double-hit lymphoma/leukemia  mimicking acute leukemia at initial  presentation.
authors.forename: Zi
authors.initials: Z
authors.lastname: Chen
authors.forename: Shimin
authors.initials: S
authors.lastname: Hu
mesh_terms: D059786:Abnormal Karyotype; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D064592:Autografts; D003520:Cyclophosphamide; D003907:Dexamethasone; D003937:Diagnosis, Differential; D004317:Doxorubicin; D005047:Etoposide; D017809:Fatal Outcome; D005434:Flow Cytometry; D016259:Genes, myc; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D007938:Leukemia / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D007964:Leukocytosis / Q000209:etiology*; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D011241:Prednisone; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics; D000069283:Rituximab / Q000008:administration & dosage; D014750:Vincristine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C000595707:BCL2 protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; C527517:ofatumumab; D011241:Prednisone